Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

One in eight new cancers are likely caused by infections—there’s an easy way to protect yourself

Many cancers associated with infection are preventable

A recent study from the World Health Organization (WHO) reveals that around 12% of worldwide cancer cases in 2024 may have been caused by infections, with the majority linked to five specific pathogens. The study, published in The Lancet Oncology, identified Helicobacter pylori (4%), human papillomavirus (4%), hepatitis B (2%), Epstein-Barr virus (1%) and hepatitis C (under 1%) as the primary culprits.

These infections are responsible for over 20 types of cancer, including stomach, liver, blood and cervical cancers. Though the proportion of cancer cases caused by infections slightly dropped between 1990 and 2002, the new figures cannot be confidently compared due to changes in data sources and quality. Infections can lead to cancer through several mechanisms, including altering host cell genes, inserting viral DNA into host DNA, and carrying oncogenes.

Infections also cause cancer indirectly through chronic inflammation and tissue damage. The study highlights that preventing infections could significantly reduce cancer rates, particularly in low- and middle-income countries where 75% of infection-related cancers occur. Vaccination programs, such as the HPV vaccine in Australia, have shown promising results in reducing infection rates and preventing associated cancers.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at scientificamerican.com →

More in Health & Medicine

Celltrion Steps Up Global Partnering Push at CPHI 2026

Celltrion is stepping up efforts to broaden its global business portfolio beyond biosimilars, using the upcoming CPHI 2026 exhibition in Milan as a platform to pursue partnerships in novel drug…

  • Celltrion intensifies global partnerships at CPHI 2026 in Milan.
  • The company hosts a 46-pyeong booth with meeting rooms and lounge.
  • Focus areas include novel drug development, contract manufacturing, and supply chain resilience.

More from Tuesday 29 September →